PGT-A, costly and unreliable yet marketed vigorously [PR]

Dr. Gleicher joins two prominent colleagues in warning against the widespread utilization of PGT-A, in an opinion paper just published in Trends in Molecular Medicine. Learn more in our press release here.

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.